



Contact:

Dr. Misha Plam

President & CEO

T: (303) 641-3669

misha.plam@amidebio.com

www.amidebio.com

Dr. John C. Hutton joins the Scientific Advisory Board of AmideBio, LLC

BOULDER, CO, April 3, 2012 – AmideBio, LLC, a privately held biopharmaceutical company, which has developed novel manufacturing processes for peptides and proteins, announced today that Dr. John Hutton has joined its Scientific Advisory Board. Professor Hutton brings over 30 years of scientific expertise in Academia, including his current position as Director of Research, Barbara Davis Center for Childhood Diabetes and Professor of Cellular & Structural Biology at UC Denver, Denver, CO.

Dr. Hutton received a B.S. and Ph.D. from the University of New South Wales, Sydney, Australia and was a Professor at Cambridge University, UK for 17 years prior to joining the faculty at UC Denver in 1996. Dr. Hutton has a distinguished career in the field of diabetes and has published more than 200 articles on various aspects of the disease.

“We are very pleased to have Dr. Hutton join our Scientific Advisory Board, says Dr. Misha Plam, President and CEO of AmideBio, and he commented: “Adding Prof. John Hutton as a senior advisor to AmideBio’s team signals our commitment to the diabetes market. John’s extensive knowledge in the area of the cell biology of insulin secretion and the pathogenesis of diabetes in both its autoimmune and metabolic forms provides the company key expertise as we transition from the technology feasibility stage to actually delivering improved methods of producing native and novel insulins. “I am delighted to join AmideBio’s Scientific Advisory Board. Their novel technological approach to the production of bioactive proteins and peptides places them in a unique position to meet the manufacturing challenges of a new generation of medicines engineered to provide better treatment for a variety of disorders from degenerative diseases to malignancies.” said Dr. John Hutton

About AmideBio:

AmideBio, based in Boulder, CO, is a biotechnology company founded on a unique process for the production of peptides and proteins, especially those that have been historically difficult to manufacture or produce in large quantities. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at inflammatory and neurodegenerative diseases. The AmideBio BioPure™ process is providing the research community with some of the most pure peptide-derived products available to date, including amyloid-beta, an important protein believed to be involved with Alzheimer disease. The Company’s platform offers an economical and environmentally sustainable process for large-scale production of Biosimilars, with the aim of providing patients with lower-cost medications. AmideBio’s technology is the foundation for internal drug discovery and development against diseases such as Diabetes and Alzheimer’s, where our BioPure™ materials have allowed for the discovery of novel targets as well as potential improvements in existing therapeutics.

- ENDS -